CAR Macrophages for SARS-CoV-2 Immunotherapy

Targeted therapeutics for the treatment of coronavirus disease 2019 (COVID-19), especially severe cases, are currently lacking. As macrophages have unique effector functions as a first-line defense against invading pathogens, we genetically armed human macrophages with chimeric antigen receptors (CA...

Descripción completa

Detalles Bibliográficos
Autores principales: Fu, Wenyan, Lei, Changhai, Ma, Zetong, Qian, Kewen, Li, Tian, Zhao, Jian, Hu, Shi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8343226/
https://www.ncbi.nlm.nih.gov/pubmed/34367135
http://dx.doi.org/10.3389/fimmu.2021.669103

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8343226/
https://www.ncbi.nlm.nih.gov/pubmed/34367135
http://dx.doi.org/10.3389/fimmu.2021.669103

Ejemplares similares